Arvee Laboratories (India) Ltd
NSE: ARVEE
Arvee Laboratories (India) Ltd (ARVEE) is a Diversified company listed on NSE: ARVEE. With a market cap of ₹181 Cr and ROCE of 9.58%, ROE of 6.79%, it operates in the Indian Diversified sector.
₹164
52W: ₹129 — ₹291
PE 86.9 · Book ₹28.5 · +475% vs bookMarket Cap₹181 Cr
Stock P/E86.9Price to Earnings
ROCE9.58%Return on Capital
ROE6.79%Return on Equity
Div. Yield0%Face Value ₹10
Strengths
- +Company is almost debt free.
Weaknesses
- −Stock is trading at 5.91 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of -3.26% over past five years.
- −Company has a low return on equity of 8.46% over last 3 years.
Shareholding Pattern
Promoters73.5%
FIIs0%
DIIs0%
Public26.5%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 26.5% | 26.5% | 26.5% | 26.5% | 26.5% | 26.5% | 26.5% | 26.5% |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.91 | 7.7 | 6.14 | 10.6 | 12.53 | 8.91 | 6.45 | 7.48 | 3.45 | 9.78 |
| Expenses | 8.22 | 7.17 | 5.35 | 9.06 | 11.03 | 8.57 | 6.23 | 7.14 | 3.33 | 8.15 |
| Operating Profit | 0.69 | 0.53 | 0.79 | 1.54 | 1.5 | 0.34 | 0.22 | 0.34 | 0.12 | 1.63 |
| OPM % | 7.74% | 6.88% | 12.87% | 14.53% | 11.97% | 3.82% | 3.41% | 4.55% | 3.48% | 16.67% |
| Net Profit | 0.21 | 0.24 | 0.12 | 0.94 | 0.98 | 0.15 | 0.07 | 0.17 | 0.01 | 1.83 |
| EPS ₹ | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 | 0.01 | 1.66 |
AI Insights
Revenue Trend
TTM revenue at ₹27.16Cr, down 29.4% YoY. OPM at 8.51%.
Debt Position
Borrowings at ₹1.03Cr. Debt-to-equity ratio: 0.05x. Healthy balance sheet.
Capex Cycle
CWIP at ₹0.81Cr (5% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 0% (+0.00pp change). Promoters hold 73.5%.
Margin & Efficiency
ROCE improving from 0% (Mar 2016) to 9.58% (Mar 2025). Working capital days: 103.55.
Valuation
PE 86.9x with 9.58% ROCE. Price is 475% above book value of ₹28.5. Dividend yield: 0%.
Recent Announcements
- Price movement 15 April 2026 - Responds to NSE price-movement query; company states no material events.
- Price movement 13 April 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
- Trading Window 27 March 2026 - Trading window closed from April 1, 2026 until two working days after results for period ended March 31, 2026.
- Price movement 6 March 2026 - 24-Dec-2025 response to NSE: company compliant, no material events; cannot explain share price movement.
- Outcome of Board Meeting 13 February 2026 - Approved unaudited results for quarter and nine months ended 31-Dec-2025; Qtr revenue Rs991.60L, nine-month Rs2,124.48L.
- Financial Year 2025 from nse
- Financial Year 2024 from nse
- Financial Year 2023 from nse